retatrutide fda approval status november 2025 Retatrutide, an investigational triple hormone receptor agonist that shows promise for weight loss in ongoing phase-3 clinical trials, is being sold openly across the internet and prescribed by licensed physicians online and Retatrutide FDA Approval 2025–2026: Phase

Semaglutide and tirzepatide are associated with the highest rates of gastrointestinal symptoms, although these tend to attenuate over time and can be mitigated with gradual titration ( Overall, the comparative evidence suggests that long-acting and multi-agonist agents maximize efficacy at the expense of higher gastrointestinal intolerance, whereas older agents provide more modest benefits with relatively favorable tolerability

Reports in the UK highlight that Retatrutide still in clinical trials is being offered on Telegram, WhatsApp and via influencers on platforms such as TikTok for next-gen fat jabs

For type 2 diabetes management Both semaglutide and tirzepatide are FDA-approved for type 2 diabetes

The benefits may be more prominent when supplementation is long-term or combined with protein

Kapoor, M

Why weight regain is so common Data show that most people who start GLP-1s for weight loss eventually quit taking them